HomeCompareMSFU vs ABBV

MSFU vs ABBV: Dividend Comparison 2026

MSFU yields 14.18% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $51.6K in total portfolio value· pulled ahead in Year 6
10 years
MSFU
MSFU
● Live price
14.18%
Share price
$23.01
Annual div
$3.26
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50.8K
Annual income
$3,412.12
Full MSFU calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MSFU vs ABBV

📍 ABBV pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMSFUABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MSFU + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MSFU pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MSFU
Annual income on $10K today (after 15% tax)
$1,205.18/yr
After 10yr DRIP, annual income (after tax)
$2,900.30/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $18,155.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MSFU + ABBV for your $10,000?

MSFU: 50%ABBV: 50%
100% ABBV50/50100% MSFU
Portfolio after 10yr
$76.5K
Annual income
$14,091.94/yr
Blended yield
18.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MSFU
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MSFU buys
0
ABBV buys
0
No recent congressional trades found for MSFU or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMSFUABBV
Forward yield14.18%3.06%
Annual dividend / share$3.26$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$50.8K$102.3K
Annual income after 10y$3,412.12$24,771.77
Total dividends collected$23.7K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MSFU vs ABBV ($10,000, DRIP)

YearMSFU PortfolioMSFU Income/yrABBV PortfolioABBV Income/yrGap
1$12,118$1,417.85$11,550$430.00+$568.00MSFU
2$14,572$1,605.73$13,472$627.96+$1.1KMSFU
3$17,396$1,804.59$15,906$926.08+$1.5KMSFU
4$20,628$2,013.45$19,071$1,382.55+$1.6KMSFU
5$24,303$2,231.24$23,302$2,095.81+$1.0KMSFU
6← crossover$28,461$2,456.80$29,150$3,237.93$689.00ABBV
7$33,142$2,688.91$37,536$5,121.41$4.4KABBV
8$38,388$2,926.33$50,079$8,338.38$11.7KABBV
9$44,243$3,167.81$69,753$14,065.80$25.5KABBV
10$50,752$3,412.12$102,337$24,771.77$51.6KABBV

MSFU vs ABBV: Complete Analysis 2026

MSFUStock

The Direxion Daily MSFT Bull 2X ETF and Direxion Daily MSFT Bear 1X ETF seek daily investment results, before fees and expenses, of 200% and 100% of the inverse (or opposite), respectively, of the performance of the common shares of Microsoft Corporation (NASDAQ: MSFT).

Full MSFU Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MSFU vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MSFU vs SCHDMSFU vs JEPIMSFU vs OMSFU vs KOMSFU vs MAINMSFU vs JNJMSFU vs MRKMSFU vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.